Stock analysts at Lifesci Capital cut their FY2025 earnings per share estimates for Astria Therapeutics in a research report issued to clients and investors on Tuesday, March 11th. Lifesci Capital ...

Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a Outperform recommendation. Analyst Price Forecast Suggests 145.23% Upside As ...

Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Protara Therapeutics in a note issued to investors on Tuesday, March 11th. Lifesci Capital analyst C. Zhu expects that the ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Immunome (NasdaqCM:IMNM) with a Outperform recommendation. Analyst Price Forecast Suggests 250.92% Upside As of March 4 ...

In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Protara Therapeutics (TARA – Research ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Molecular Partners AG - Depositary Receipt () (NasdaqGS:MOLN) with a Outperform recommendation. As of March 4 ...

LifeSci Capital initiated coverage of Protara Therapeutics (TARA) with an Outperform rating and $22 price target Effectively assess a stock's risks and opportunities with a clear breakdown of its ...

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of $30.00. The company’s shares clo ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- LifeSci Communications today announced key leadership appointments and promotions designed to support its continued growth and strengthen its service ...

In addition to LifeSci Capital, Zymeworks also received a Buy from J.P. Morgan’s Brian Cheng in a report issued on March 6. However, on March 7, H.C. Wainwright reiterated a Hold rating on ...

The firm decreased its portfolio allocation in IMNM by 15.15% over the last quarter. EcoR1 Capital holds 3,879K shares representing 4.74% ownership of the company. No change in the last quarter.